These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1217 related articles for article (PubMed ID: 17687129)

  • 1. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia.
    Manco-Johnson MJ; Abshire TC; Shapiro AD; Riske B; Hacker MR; Kilcoyne R; Ingram JD; Manco-Johnson ML; Funk S; Jacobson L; Valentino LA; Hoots WK; Buchanan GR; DiMichele D; Recht M; Brown D; Leissinger C; Bleak S; Cohen A; Mathew P; Matsunaga A; Medeiros D; Nugent D; Thomas GA; Thompson AA; McRedmond K; Soucie JM; Austin H; Evatt BL
    N Engl J Med; 2007 Aug; 357(6):535-44. PubMed ID: 17687129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of secondary prophylaxis in children with severe hemophilia.
    Manco-Johnson MJ; Nuss R; Geraghty S; Funk S; Kilcoyne R
    Am J Hematol; 1994 Oct; 47(2):113-7. PubMed ID: 8092125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of late prophylaxis in hemophilia on joint status: a randomized trial.
    Manco-Johnson MJ; Lundin B; Funk S; Peterfy C; Raunig D; Werk M; Kempton CL; Reding MT; Goranov S; Gercheva L; Rusen L; Uscatescu V; Pierdominici M; Engelen S; Pocoski J; Walker D; Hong W
    J Thromb Haemost; 2017 Nov; 15(11):2115-2124. PubMed ID: 28836341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tailored frequency-escalated primary prophylaxis for severe haemophilia A: results of the 16-year Canadian Hemophilia Prophylaxis Study longitudinal cohort.
    Feldman BM; Rivard GE; Babyn P; Wu JKM; Steele M; Poon MC; Card RT; Israels SJ; Laferriere N; Gill K; Chan AK; Carcao M; Klaassen RJ; Cloutier S; Price VE; Dover S; Blanchette VS
    Lancet Haematol; 2018 Jun; 5(6):e252-e260. PubMed ID: 29731369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylaxis for severe haemophilia: clinical challenges in the absence as well as in the presence of inhibitors.
    Fischer K; Valentino L; Ljung R; Blanchette V
    Haemophilia; 2008 Jul; 14 Suppl 3():196-201. PubMed ID: 18510542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review of antihemophilic factor injection for the routine prophylaxis of bleeding episodes and risk of joint damage in severe hemophilia A.
    Rossbach HC
    Vasc Health Risk Manag; 2010 Mar; 6():59-68. PubMed ID: 20234780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efanesoctocog Alfa Prophylaxis for Children with Severe Hemophilia A.
    Malec L; Peyvandi F; Chan AKC; Königs C; Zulfikar B; Yuan H; Simpson M; Álvarez Román MT; Carcao M; Staber JM; Dunn AL; Chou SC; d'Oiron R; Albisetti M; Demissie M; Santagostino E; Yarramaneni A; Wong N; Abad-Franch L; Gunawardena S; Fijnvandraat K;
    N Engl J Med; 2024 Jul; 391(3):235-246. PubMed ID: 39018533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prevention of joint damage in hemophilic children with early prophylaxis].
    Kreuz W; Escuriola Ettingshausen C; Funk M; Pons S; Schmidt H; Kornhuber B
    Orthopade; 1999 Apr; 28(4):341-6. PubMed ID: 10335528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcome of individualized prophylactic treatment of children with severe haemophilia.
    van den Berg HM; Fischer K; Mauser-Bunschoten EP; Beek FJ; Roosendaal G; van der Bom JG; Nieuwenhuis HK
    Br J Haematol; 2001 Mar; 112(3):561-5. PubMed ID: 11260054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors.
    Leissinger C; Gringeri A; Antmen B; Berntorp E; Biasoli C; Carpenter S; Cortesi P; Jo H; Kavakli K; Lassila R; Morfini M; Négrier C; Rocino A; Schramm W; Serban M; Uscatescu MV; Windyga J; Zülfikar B; Mantovani L
    N Engl J Med; 2011 Nov; 365(18):1684-92. PubMed ID: 22047559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study.
    Collins P; Faradji A; Morfini M; Enriquez MM; Schwartz L
    J Thromb Haemost; 2010 Jan; 8(1):83-9. PubMed ID: 19817995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Musculoskeletal health of subjects with hemophilia A treated with tailored prophylaxis: Canadian Hemophilia Primary Prophylaxis (CHPS) Study.
    Hilliard P; Zourikian N; Blanchette V; Chan A; Elliott B; Israels SJ; Nilson J; Poon MC; Laferriere N; Van Neste C; Jarock C; Wu J; McLimont M; Feldman B
    J Thromb Haemost; 2013 Mar; 11(3):460-6. PubMed ID: 23301594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of primary and secondary prophylaxis on the clinical expression of joint damage in children with severe haemophilia A. Results of a multicenter non-concurrent cohort study.
    Schobess R; Kurnik K; Friedrichs F; Halimeh S; Krümpel A; Bidlingmaier C; Nowak-Göttl U
    Thromb Haemost; 2008 Jan; 99(1):71-6. PubMed ID: 18217137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Orthopaedic evaluation in children with severe haemophilia A or B submitted to primary prophylaxis therapy in a coagulopathy treatment centre.
    De Podestá Haje D; Ono F; De Oliveira GB; Almeida J; De Paula JC; Batista Neto LV; Silva Barros SB
    Haemophilia; 2011 Mar; 17(2):228-32. PubMed ID: 21070500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study.
    Feldman BM; Pai M; Rivard GE; Israels S; Poon MC; Demers C; Robinson S; Luke KH; Wu JK; Gill K; Lillicrap D; Babyn P; McLimont M; Blanchette VS;
    J Thromb Haemost; 2006 Jun; 4(6):1228-36. PubMed ID: 16706965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between factor VIII replacement therapy and joint damage in severe haemophilia.
    Lowe GD
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S3-5. PubMed ID: 9351528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Joint Aspiration for Acute Hemarthrosis in Children Receiving Factor VIII Prophylaxis for Severe Hemophilia: 11-year Safety Data.
    Manners PJ; Price P; Buurman D; Lewin B; Smith B; Cole CH
    J Rheumatol; 2015 May; 42(5):885-90. PubMed ID: 25729030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing prophylaxis with episodic treatment in haemophilia A: implications for clinical practice.
    Manco-Johnson M
    Haemophilia; 2007 Sep; 13 Suppl 2():4-9. PubMed ID: 17685917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discontinuing early prophylaxis in severe haemophilia leads to deterioration of joint status despite low bleeding rates.
    Nijdam A; Foppen W; De Kleijn P; Mauser-Bunschoten EP; Roosendaal G; van Galen KP; Schutgens RE; van der Schouw YT; Fischer K
    Thromb Haemost; 2016 May; 115(5):931-8. PubMed ID: 26791021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors.
    Mahlangu J; Oldenburg J; Paz-Priel I; Negrier C; Niggli M; Mancuso ME; Schmitt C; Jiménez-Yuste V; Kempton C; Dhalluin C; Callaghan MU; Bujan W; Shima M; Adamkewicz JI; Asikanius E; Levy GG; Kruse-Jarres R
    N Engl J Med; 2018 Aug; 379(9):811-822. PubMed ID: 30157389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 61.